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Abstract
Background: To date, all studies conducted on breast cancer diagnosis have focused on the expression of the full-
length 66-kDa estrogen receptor alpha (ERα66). However, much less attention has been paid to a shorter 46-kDa
isoform (ERα46), devoid of the N-terminal region containing the transactivation function AF-1. Here, we investigated
the expression levels of ERα46 in breast tumors in relation to tumor grade and size, and examined the mechanism
of its generation and its specificities of coregulatory binding and its functional activities.
Methods: Using approaches combining immunohistochemistry, Western blotting, and proteomics, antibodies
allowing ERα46 detection were identified and the expression levels of ERα46 were quantified in 116 ERα-positive
human breast tumors. ERα46 expression upon cellular stress was studied, and coregulator bindings, transcriptional,
and proliferative response were determined to both ERα isoforms.
Results: ERα46 was expressed in over 70% of breast tumors at variable levels which sometimes were more
abundant than ERα66, especially in differentiated, lower-grade, and smaller-sized tumors. We also found that ERα46
can be generated via internal ribosome entry site-mediated translation in the context of endoplasmic reticulum
stress. The binding affinities of both unliganded and fully-activated receptors towards co-regulator peptides
revealed that the respective potencies of ERα46 and ERα66 differ significantly, contributing to the differential
transcriptional activity of target genes to 17β estradiol (E2). Finally, increasing amounts of ERα46 decrease the
proliferation rate of MCF7 tumor cells in response to E2.
Conclusions: We found that, besides the full-length ERα66, the overlooked ERα46 isoform is also expressed in a
majority of breast tumors. This finding highlights the importance of the choice of antibodies used for the diagnosis
of breast cancer, which are able or not to detect the ERα46 isoform. In addition, since the function of both ERα
isoforms differs, this work underlines the need to develop new technologies in order to discriminate ERα66 and
ERα46 expression in breast cancer diagnosis which could have potential clinical relevance.
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Background
Breast cancer is a major public health concern because its
incidence continues to rise. It is the second most common
cancer overall and by far the most frequent cancer among
women [1]. The etiology of breast cancer is multifactorial,
and although the mechanisms of carcinogenesis remain
poorly defined the role of hormones is recognized as a
major risk factor in breast cancer development, in particu-
lar 17β estradiol (E2) and its derivatives.
Estrogen receptor (ER)α is one of two ERs and is in-
volved in several key aspects of breast cancer diagnosis [2].
Firstly, ERα protein immunoreactivity in the nucleus of
mammary epithelial cells is systematically evaluated and
quantified during anatomopathological diagnosis, with 70%
of breast cancers initially described as ERα-positive [2].
Secondly, ERα expression in breast cancers correlates with
improved survival rates and reduced risk of recurrence and
metastases [3–5]. Finally, the blockade of ERα activity
represents a major targeted therapy for ERα-positive breast
cancer, with tamoxifen and aromatase inhibitors having
already benefitted millions of women [6]. Despite the
success of these treatments, 30 to 40% of patients develop
resistance [7]. This highlights the need for further in-depth
characterization of ERα-positive tumors and a full under-
standing of the mechanisms underlying the disease in
order to propose new therapeutic approaches.
In addition to the “classic” full-length 66-kDa ERα
(ERα66) which harbors the two activation functions, AF-1
and AF-2, two other isoforms of 46 kDa (ERα46) and
36 kDa (ERα36) have been characterized. ERα36 differs from
ERα66 by lacking both transcriptional activation domains
(AF-1 and AF-2) and encoding a unique 29 amino acid
sequence [8]. In contrast, ERα46 only lacks the first 173 N-
terminal amino acids which harbors AF-1 and is thus com-
pletely identical to the amino acids 174 to 595 of ERα66
(Fig. 1a). ERα46 has been reported to be expressed in vari-
ous cell types such as human osteoblasts [9], macrophages
[10], and vascular endothelial cells [11], but also in cancer
cells such as colorectal tumor tissues [12] and tamoxifen-
resistant breast cancer cell lines [13]. Mechanisms regulating
both the expression of ERα46 and its functions remain es-
sentially unknown. It can be generated by either alternative
splicing [14], proteolysis [15], or an alternative initiation of
translation via an internal ribosome entry site (IRES) [16].
This latter mechanism generates two different proteins from
a single RNA. A few studies have suggested that ERα46
plays an inhibitory role in the growth of cancer cell lines,
suggesting that ERα46 could affect tumor progression. The
overexpression of ERα46 in proliferating MCF7 cells
provoked cell cycle arrest in G0/G1 phase and inhibited
ERα66-mediated estrogenic induction of the AF-1-sensitive
reporters c-fos and cyclin D1, as well as estrogen-responsive
element (ERE)-driven reporters [14, 17]. It was also shown
that ERα46 inhibits growth and induces apoptosis in human
HT-29 colon adenocarcinoma cells [12]. This inhibition
likely occurs through competition between ERα66 and
ERα46 homodimers and heterodimers for binding to the
ERE [17]. The role of the AF-1-deficient ERα46 isoform has
also been questioned in vivo using mice deficient in the ERα
A/B domain (named ERαAF-10), which express only a short
49-kDa isoform that is functionally similar to ERα46. These
ERαAF-10 mice revealed a complete infertility phenotype
[18] that was associated with an altered proliferative effect of
E2 on the uterine epithelium and a loss of its transcriptional
response in this tissue [19].
Thus, the roles and functions of this ERα46 isoform
appear to be different from those of full-length ERα66. The
expression level of this truncated isoform in human breast
tumors remains unknown, even though the expression of a
47-kDa isoform of ERα in human breast cancers was
reported more than two decades ago [20]. Currently,
several antibodies are used for immunohistochemical
detection of ERα in human breast tumor diagnosis but
most of them have not yet been thoroughly characterized
in terms of ERα46 recognition.
In this study, we first characterized the various antibodies
commonly employed in immunohistochemical diagnosis
for their ability to detect ERα46. We then analyzed the
relative expression of the ERα isoforms in a panel of 116
ERα-positive breast tumors. We also examined the mech-
anism of ERα46 generation and its specificities in term of
coregulator binding and of functional activities.
Methods
Cell culture
MDA-MB231 and MDA-MB231 cells stably expressing
ERα66 (MDA-ERα66; [21]) or ERα46 (MDA-ERα46; [22])
or transiently transfected with pSG5Flag-ERα36 (kindly pro-
vided by M. Le Romancer) were maintained in Dulbecco’s
modified Eagle’s medium (DMEM; Sigma) supplemented
with 5% fetal calf serum (FCS; Biowest) and antibiotics
(Sigma) at 37 °C under 5% CO2. Media used to maintain
cells expressing either ER isoforms also included hygromy-
cin (Calbiochem; 0.8 mg/ml). We also transiently transfected
MDA cells with either the pcDNA3.1 plasmid, encoding the
cDNA of ERα46, or a mutated version, ERα46kDa0, using
the TransIT®-BrCa Transfection Reagent (Euromedex,
France). This mutated plasmid was obtained by subcloning
a fragment from ERα66 that contains an AUG/UCG muta-
tion at codon 174 and an AUG/AUA mutation at codon
176 [16]. Stably transfected MCF7 sub-clones MCF7-B0
(control) and MCF7-B1 and MCF7-B2 overexpressing
ERα46 were obtained by transfecting MCF7 cells with
pcDNA6/TR plasmid and pcDNA4/TO expression vector
containing or not the ERα46 cDNA sequence (T-Rex
system, Invitrogen) with jetPEI reagent (Polyplus transfec-
tion). The clones were selected with 5 μg/ml blasticidin and
100 μg/ml zeocin (Invitrogen). Individual clones were
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isolated and grown in a medium containing selective antibi-
otics to maintain selection pressure. Expression of the pro-
teins of interest was induced by a 48-h treatment of MCF7
sub-clones with 1 μg/ml tetracyclin.
Immunohistochemistry
Cells were formalin-fixed and paraffin-embedded using
the Shandon™ Cytoblock™ Cell Block Preparation System,
according to the manufacturer’s protocol. Immunohisto-
chemistry was performed with a Dako Autostainer Link
48 on 3-μm sections. Antigen retrieval was performed
using a Dako PT Link pressure cooker in pH 6.0 citrate
buffer. An EnVision™ system was used for antibody detec-
tion. The anti-Flag (M2; Sigma-Aldrich) and a panel of
anti-ERα antibodies (SP1 (Abcam), HC20 (SantaCruz),

















ER  66 
ER  46
1 184 264 302 553 595











MDA MDA-46kDa MDA-66kDa MDA-36kDaMCF7
ER  36
174 264 302 448 475
LBDDBD H
Fig. 1 Recognition of estrogen receptor alpha (ERα) isoforms by antibodies used for human breast cancer diagnosis. a Schematic representation
of the ERα66, ERα46, and ERα36 isoforms. The location of the known epitopes used for the generation of antibodies is indicated. b Representative
Western blot analyses with the SP1 antibody on extracts from MDA-MB-231 cells transfected with plasmids encoding either ERα46 (MDA-46 kDa)
or ERα66 (MDA-66 kDa) and from MCF7 cells which express both isoforms, or c with the Anti-Flag antibody on extracts from MDA-MB-231 cells
transfected with plasmids encoding the ERα36 isoform. d The different antibodies used in breast cancer diagnosis (1D5, 6 F11, SP1, and EP1) were
tested for their ability to recognize either ERα66, ERα46, or both isoforms in immunocytochemistry experiments performed in MCF7, MDA-ERα46,
and MDA-ERα66 or MDA-ERα36 cells. e Representative picture of Western blot experiments evaluating the expression of both ERα isoforms in
MCF-7 cells, as determined by the different antibodies indicated. Protein extracts prepared from MDA cells were used as an ERα-negative control.
AF activation function, DBD DNA-binding domain, LBD ligand-binding domain
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Human breast cancer sample collection
The retrospective study used tumors samples from pa-
tients diagnosed with invasive breast carcinoma, estab-
lished as being ERα-positive on a previously performed
biopsy (see Additional file 1 (Figure S1) for clinical param-
eters of the patients used). The diagnosis was performed
with the 6 F11 or 1D5 antibodies between 2011 and 2014.
Tumors were frozen in 1.5-ml cryotubes using the Snap-
FrostII™ fast freezing system (Excilone, France) and stored
at –80 °C. Patients with an ipsilateral recurrence of breast
cancer who had received neoadjuvant chemotherapy or
chemotherapy treatment for another disease or who re-
ceived thoracic radiation therapy (recurrence or another
pathology) were excluded. All tumors were classified by
the anatomopathologist (human epidermal growth factor
receptor-2 (HER2) status, tumor size, ERα overexpression,
lymph node involvement, histological type) and were
graded according to Elstone and Ellis’ guidelines [23]. The
analysis was performed on a series of 116 ERα-positive in-
vasive ductal or lobular breast carcinomas (22 grade I, 60
grade II, and 34 grade III).
Western blots on tumor samples
Samples of each tumor were lysed in cold lysis buffer
(150 mM NaCl, 50 mM Tris-HCl pH 7.5, 0.1% SDS, 1 mM
ethylenediaminetetraacetic acid (EDTA), 5 mM NaF, 1 mM
orthovanadate, 0.5 mM 1,4-dithiothreitol (DTT), and prote-
ase inhibitors) using a Precellys Homogeniser (Bertin Tech-
nologies, France). Proteins were separated on a 10% SDS-
PAGE gel and transferred to a nitrocellulose membrane.
After blocking, membranes were incubated overnight with
the primary antibody (anti-ERα (SP1) or anti-GAPDH (6C5);
Santa Cruz). Subsequently, blots were incubated with a
horseradish peroxidase (HRP)-conjugated secondary anti-
body (anti-rabbit; Cell Signaling) and visualized by enhanced
chemiluminescence (ECL) detection according to the manu-
facturer's instructions (Amersham Biosciences, CT) using a
ChemiDoc™ Imaging System (Bio-Rad). Bands corresponding
to ERα46 and ERα66 were quantified using ImageJ densi-
tometry, and the ratio of the band intensities was calculated.
Endoplasmic reticulum stress
MDA-66 kDa or MCF7 cells were seeded in six-well plates.
At 80% confluence, the cells were subjected to 6 h of stress
with DTT (Euromedex) or thapsigargin (Sigma) as indicated,
then rinsed in phosphate-buffered saline (PBS), lysed in SDS
buffer (5% SDS, 10% glycerol, 80 mM Tris pH6.8), and soni-
cated. Western blot analyses were then performed on 4–20%
denaturing polyacrylamide “stain-free” gels (BioRad).
Immunoprecipitation and proteomic analysis
ERα-enriched protein fractions from tumor protein extracts
were obtained through immunoprecipitation using the anti-
human ERα primary HC20 antibody. Following their
purification using Protein G sepharose beads, a first Western
blot was performed to check the efficiency of the immuno-
precipitation. In parallel, the immunoprecipitate was diluted
with Laemmli buffer, then separated by SDS-PAGE using a
short and low-voltage electrophoretic migration. After
Instant Blue staining, the bands corresponding to ERα46
and ERα66 were respectively excised from the gel. Proteins
were in-gel digested by trypsin, and resulting peptides were
extracted from the gel and analyzed by nano-liquid chroma-
tography coupled to tandem mass spectrometry (LC-MS/
MS) using an ultimate 3000 system (Dionex, Amsterdam,
Netherlands) coupled to an LTQ-Orbitrap Velos mass spec-
trometer (Thermo Scientific, Bremen, Germany).
The LTQ-Orbitrap Velos was operated in data-dependent
acquisition mode with the Xcalibur software. Survey scan
MS spectra were acquired in the Orbitrap in the 300–2000
m/z range with the resolution set to a value of 60,000. The
twenty most intense ions per survey scan were selected for
collision-induced dissociation fragmentation, and the result-
ing fragments were analyzed in the linear ion trap (LTQ,
parallel mode, target value 1e4). Database searches from the
MS/MS data were performed using the Mascot Daemon
software (version 2.3.2, Matrix Science, London, UK). The
following parameters were set for creation of the peak
lists: parent ions in the mass range 400–4500, no
grouping of MS/MS scans, and threshold at 1000. Data
were searched against SwissProt 20130407. Mascot results
were parsed with the in-house developed software MFPaQ
version 4.0 (Mascot File Parsing and Quantification)
(http://mfpaq.sourceforge.net/) and protein hits were
automatically validated with a false discovery rate (FDR)
of 1% on proteins and 5% on peptides (minimum peptide
length of six amino acids).
Plasmids, lentiviral production, and luciferase assay
cDNA coding for the A/B (amino acids 2–173) domain of
the human ESR1 gene encoding ERα was amplified by poly-
merase chain reaction (PCR) and cloned into the SpeI and
NcoI sites of the pTRIP CRF1AL2 bi-cistronic vector that
encodes both the Renilla luciferase (LucR) and Firefly lucif-
erase (LucF2CP) genes separated by this putative IRES-ERα
sequence [24]. The final construct was verified by sequen-
cing. In such a transgene, LucR expression is cap-dependent
whereas LucF expression is IRES-dependent; thus, the level
of IRES activity can be deduced from the LucF/LucR ratio.
The production of lentiviral particles was performed in
HEK293 cells. Transduced MDA-MB 231 cells (MDA-A/B)
were subjected to ER stress as indicated. To test whether
the stress-induced increase in LucF activity was not due to
the generation of mono-cistronic LucF transcripts via an in-
ternal promoter or cryptic splicing, MDA-Lenti-AB (1/10)
cells were exposed to two siRNAs-lucR and treated with
5 mM DTT or 100 nM thapsigargin. As control, cells were
treated with scrambled siRNA. After a PBS wash, cells were
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frozen at –80 °C. Luciferase measurements were performed
with a LB960 luminometer (Berthold) using the dual re-
porter assay kit (E1960; Promega) according to the manufac-
turer’s recommendations.
RT-qPCR
MDA-MB231, MDA-ERα46, and MDA-ERα66 cells were
plated in 9-cm diameter dishes in DMEM/0.5% charcoal-
stripped FCS (csFCS) containing appropriate antibiotics in
order to reach confluency 3 days later. Cells were then
treated with 10–8 M E2 final for 4 h or with a similar
volume of ethanol (vehicle). Total RNAs were then purified
using the Trizol™ reagent (Life Technologies, Inc.) according
to the manufacturer’s instructions. RNA (2 μg) was used as
a template for reverse transcription (RT) by the M-MLV re-
verse transcriptase (Invitrogen) and Pd(N)6 random hexam-
ers (Amersham Pharmacia Biosciences). Quantitative PCR
used on 2 μl of 1/10th diluted RT reactions and 1 μM of
specific oligonucleotides and were performed on BioRad
CFX96 machines using BioRadiQ SYBR Green supermix
with 50 rounds of amplification followed by determination
of melting curves. Primers for RT-PCR were designed under
the QuantPrime design tool (http://www.quantprime.de
[25]). Independent triplicate experiments were conducted
twice, and all values were normalized to Rplp0 mRNA. Sig-
nificant variations were evaluated using the GraphPadPr-
ism™ software.
Coregulator-peptide interaction profiling
Ligand-mediated modulation of the interactions between
the ERα46 and ERα66 proteins and their coregulators was
characterized by a MARCoNI (Microarray Assay for Real-
time Coregulator-Nuclear receptor Interaction; PamGene
International BV, the Netherlands). This method has been
described previously [26, 27]. Briefly, each array was incu-
bated with a reaction mixture of crude lysates from MDA-
MB-231 cells stably expressing each isoform of ERα46 or
ERα66 on buffer F (PV4547; all Invitrogen) and vehicle (2%
DMSO in water) with or without the receptor ligands at the
indicated concentrations. ERα66 was quantified by enzyme-
linked immunosorbent assay (ELISA; Active Motif, USA)
and ERα46 was normalized to ERα66 by Western blot ana-
lyses. SP1 antibody which specifically recognized both iso-
forms was used to detect the ERα bound on the PamChip
microarray. For both ERα46 and ERα66 receptors, a dose-
response curve was performed from 10–12 to 10–7 M E2 to
directly compare their response to E2. For measurements
of antagonist effects with 4-hydroxytamoxifen and Fulves-
trant, 6.3 nM ( 10–8.2M) E2 was applied since both recep-
tors were fully active at that concentration. Incubation
was performed at 20 °C in a PamStation96 (PamGene
International). Receptor binding to each peptide on the
array was detected by SP1 antibody. The secondary anti-
rabbit antibody conjugated to fluorescein and the goat
anti-mouse antibody conjugated to fluorescein were used
and given a fluorescent signal, which was further quanti-
fied by analysis of .tiff images using BioNavigator software
(PamGene International).
Statistical analyses
Comparisons between groups were performed using the
Mann-Whitney rank sum test for continuous variables.
Correlations between continuous variables were evaluated
using the Spearman's rank correlation test. All P values
are two-sided. For all statistical tests, differences were
considered significant at the 5% level. Statistical analyses
were performed using the STATA 13.0 software (STATA
Corp, College Station, TX) or GraphPad Prism v.5.
Results
Characterization of the anti-ERα antibodies commonly
used for breast tumor diagnosis
Apart from lacking the A/B domain and thus the AF-1
transactivation function, the ERα46 isoform is completely
identical to the ERα66 isoform (Fig. 1a). Therefore, to
characterize the expression of ERα46 in breast tumors, an
antibody must be used that is directed against the C-
terminal domain. This excludes 1D5, one of the first mono-
clonal antibodies to be available against ERα for tumor
diagnosis [28], targeting an epitope in the A/B domain
(Fig. 1a). Later on, the respective murine and rabbit mono-
clonal antibodies 6 F11 and SP1, with improved specificities
compared to the 1D5 clone, became extensively used for
diagnosis [29, 30]. More recently, the monoclonal rabbit
antibody EP1 was commercialized. However, whereas the
SP1 epitope is known to be in the C-terminal domain, the
abilities of the 6 F11 and EP1 antibodies to recognize
ERα46 have not, to our knowledge, been reported.
To test this, we used control ERα-negative MDA-MB-231
cells and MDA cells engineered to stably express either the
ERα46 or ERα66 isoform or to transiently express the Flag-
tagged ERα36 protein, alongside MCF7 cells co-expressing
both proteins (Fig. 1b and c, and Additional file 1: Figure S2).
Interestingly, a small amount of ERα46 expression was
found in MDA 66-kDa cells, presumably due to an alternative
initiation of translation at Met 174 and/or Met 176 as previ-
ously suggested [16]. Immunocytochemistry performed on
these five cell lines demonstrated that, among the four tested
antibodies (1D5, 6 F11, SP1, and EP1), only SP1 was able to
specifically detect the ERα46 isoform in the MDA 46-kDa
cells (Fig. 1e). Of note, none of these antibodies was able to
recognize the ERα36 isoform by immunocytochemistry.
The immunoreactivity of the different antibodies was also
tested by immunoblotting with the HC-20 antibody, which is
frequently used in Western blot analyses, but not for diagno-
sis since it is a polyclonal rabbit antibody (Fig. 1e). Whereas
EP1 and 6 F11 only detected ERα66, the HC-20 and SP1
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antibodies recognized both ERα46 and ERα66, which is well
in line with the immunocytochemistry results. We also no-
ticed that the 1D5 antibody had a quasi-undetectable re-
activity when used in this procedure. Altogether, these
data demonstrate that from the set of antibodies com-
monly used for breast cancer diagnosis, the SP1 antibody
is the only one able to recognize the ERα46a isoform by
immunohistochemistry.
Quantification of ERα46 in human breast carcinomas
Using SP1 antibody, we next performed Western blotting
of 116 ERα-positive breast tumor samples (initially charac-
terized with the 6 F11 or 1D5 antibodies) to compare the
relative abundance of ERα46 and ERα66. Patients included
in this study had not have received any neoadjuvant ther-
apy. Most of the breast tumors (70%) expressed both iso-
forms, though at varying levels (Fig. 2a and b). The
ERα46/ERα66 ratio varied from 0 to 3.48, with a mean
average of 0.37 and a median of 0.16. Furthermore, even
though the vast majority of tumors expressed lower levels
of ERα46 than ERα66, 10% of the tumors tested expressed
predominantly the shorter isoform (Fig. 2c).
We next analyzed the relationship between clinical pa-
rameters (grade and size of tumor) and ERα46 expression.
We found that high-grade tumors correlated with lower
ERα46 expression since 91% of grade I tumors expressed
ERα46, whereas this figure was 75 and 62% for grades II
and III, respectively (Fig. 2d). Moreover, the ERα46/ERα66
ratio of the relative expression of these isoforms was also
significantly higher in low-grade tumors compared to tu-
mors of grades II and III which are highly dedifferentiated
(P = 0.0024 and P = 0.0059, respectively; see Fig. 2e). The
abundance of ERα46 was also inversely correlated with
tumor size (Fig. 2f). Finally, we classified our samples
using a size parameter usually used by the American Joint
Committee on Cancer (AJCC) to characterize tumor
evolution, which is set at a 2-cm cut-off. Using this classifi-
cation, we found that ERα46 expression was higher in
small-sized tumors compared to tumors greater than 2 cm
in diameter (P = 0.0039; Fig. 2g). Interestingly, even though
there was a few HER2-positive tumors among our sam-
ples, a significant correlation was found between HER2 ex-
pression and expression of ERα46, indicating that HER2-
positive tumors have low abundance of ERα46 (Additional
file 1: Figure S3). All other parameters, including necrosis,
were not significant.
A few studies have shown that 8% of tumors diagnosed
as ERα-negative using the 1D5 antibody were actually
positive for ERα when tested with next-generation anti-
bodies such as SP1 [29–31]. The authors did not take
into account the presence of ERα46, which cannot be
detected by the 1D5 antibody. We therefore explored
the possibility that these tumors may not express ERα66
but only ERα46 by evaluating the expression of the
ERα46 isoform in a series of 19 tumors identified as
ERα-negative using the 6 F11 antibody. However, none
of these samples were found to express the short ERα46
isoform. A representative sample is shown in Fig. 2a.
This study remains preliminary and should be extended
to a larger sample series (in process).
Altogether, these data obtained by analyzing the expres-
sion of ERα46 in a panel of 116 ERα-positive breast tumors
highlights the fact that ERα46 was expressed in more than
70% of cases. Furthermore, although the expression of this
short isoform was highly variable, it correlated with the
tumor evolution stage with a higher expression in low-
grade tumors and lower expression in tumors that were
larger, less differentiated, and of higher-grade.
Identification of the ERα46 isoform
Although the bands observed by Western blot analysis
were of the expected sizes, we wanted to confirm the na-
ture of the detected proteins. To reach this aim, we puri-
fied the ERα proteins from MCF7 cells and from lysates of
four tumor samples by immunoprecipitating the two ERα
isoforms using the anti-human ERα primary HC20 anti-
body (Additional file 1: Figure S4A). After separation by
SDS-PAGE, the gel bands corresponding to the 46-kDa
and 66-kDa proteins were excised and further digested for
proteomic analysis. In MCF7 cells (Table 1), 24.4% of the
ERα66 sequence was covered, including a peptide in the
N-terminal domain of amino acids 9–32. Importantly, and
as expected, although 23.3% of the ERα46 sequence was
detected, no peptide from the N-terminal A/B domain
was identified. Proteomic analysis of immunoprecipitated
ERα proteins from four tumor samples respectively cov-
ered 25% of the ERα66 sequence and 15.3% of the ERα46
sequence (Additional file 1: Figure S4B and S4C). Again,
although peptides 184–206, 402–412, and 450–457 were
found in the 46 kDa-sized band, no peptides located
before the ATG at codon 174 were detected. The first
peptide found is 184-206. Therefore, although we were
unable to characterize the start codon of ERα46, we con-
firm for the first time that the 46-kDa band identified in
Western blot analyses of ERα-positive tumors is without
doubt a shorter isoform of ERα.
ERα46 can be expressed following alternative initiation of
translation in response to stress
It has already been proposed that an alternative initiation
of translation could participate in ERα46 generation
through an IRES and the presence of two other potential
initiation codons (AUG174/176) in the mRNA coding
sequence for amino acids 2–173 of ERα [16]. In line with
this potential mechanism, we were able to detect ERα46
by Western blot analysis in MDA cells transfected with
full-length ERα66 (Fig. 1b). In order to definitively confirm
this hypothesis, we analyzed ERα46 expression in MDA
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Fig. 2 Evaluation of the relative expression of estrogen receptor alpha (ERα)46 and ERα66 in human ERα-positive breast tumors. a Representative
image of Western blot of human ERα-positive breast tumor samples blotted with an anti-ERα antibody (SP1). One result representative of an
ERα-negative tumor is also shown. The MDA-ER66 cell line that co-expresses ERα66 and ERα46 was used as a positive control. The ERα46/ERα66
expression ratio is indicated below each lane. b The summarized data expressed as percentages of tumors expressing ERα46 or not. c Distribution
of the ERα46/ERα66 expression ratio among the 116 tumor samples. d The number and grade of tumors expressing ERα46. e The ERα46/ERα66
expression ratio depending upon tumor grade (I, II, or III). f, g The ERα46/ERα66 expression ratio in correlation to tumor size. The whiskers in the
boxplots indicate the 10–25% and 75–90% intervals
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cells transfected with an ERα46 construct in which the
two potential initiation codons of ERα46 (AUG174/176)
were mutated (ERα460). As shown in Fig. 3a, ERα46
expression was not detected using this ERα460 construct,
demonstrating that the two potential initiation codons are
necessary to generate the ERα46 isoform.
We next sought to determine how this putative IRES
sequence can be stimulated. IRESs were found to be acti-
vated in tumor cells continually subjected to diverse stress
conditions of the tumor microenvironment [32, 33]. Fur-
thermore, accumulating evidence argues for the presence of
chronic stress of endoplasmic reticulum or unfolded
protein response (UPR) in different types of cancers, in-
cluding breast cancer (for a recent review, see [34]). Given
the preferential shift towards cap-independent mRNA
translation during UPR [35], we hypothesized that endo-
plasmic reticulum stress might stimulate the translation of
open-reading frames downstream of the major initiation
codon. To address this question, we transduced MDA-MB-
231 cells with a bi-cistronic lentivector carrying the cDNA
sequence of the A/B domain (amino acids 2–173) of ERα
cloned between LucR and LucF (Fig. 3b). In these trans-
duced MDA cells (Fig. 3c) as well as in transduced MCF7
cells (Additional file 1: Figure S5A), the LucF/LucR ratios
Table 1 Proteomic analysis of the 46-kDa protein detected in tumor samples










MCF7 IP46 759 23.3 14 212–231 No 556–581
IP66 440 24.4 12 009–032 Yes 556–581
Tumor 1 IP46 96 8.0 5 402–412 No 556–581
IP66 52 4.4 1 556–581 No 556–581
Tumor 2 IP 46 228 15.3 5 184–206 No 556–581
IP 66 522 25.0 10 38–48 Yes 556–581
Tumor 3 IP 46 65 3.0 1 450–467 No 450–467
Tumor 4 IP 46 35 1.8 1 402–412 No 402–412
Proteomic analysis results from the different cell lines and the four breast tumor samples
The % of sequence coverage corresponds to the number of amino acid residues identified in the proteomic analysis divided by the total number of amino acid
residues in the protein sequence. The Mascot score is described in [52]. It uses statistical methods to assess the validity of a match. This enables a simple rule to
be used to judge whether a result is significant or not. We report scores as -10*LOG10(P), where P is the absolute probability. A probability of 10-20 thus becomes





Fig. 3 IRES-mediated generation of estrogen receptor alpha (ERα)46. a A representative image of a Western blot of extracts from MDA-MB-231
cells transfected with constructs expressing either ERα46, wild-type ERα66, or an ERα66 cDNA harboring mutated ATG174/176 codons (ERα460),
illustrating the loss of expression of ERα46 in cells transfected with the vector encoding ERα460. b Scheme illustrating the bi-cistronic pTRIP-
hERaAB-L2 vector harboring the Renilla luciferase (LucR) and Firefly luciferase (LucF(2CP)) cistrons separated by the sequence coding for the A/B
domains of the human ERα66. c, d Stress-induced alternative initiation of translation. c MDA-MB-231 cells transduced with lentivirus expressing
the LucR-hERaAB-LucF construct were subjected to 6 h of stress with 1,4-dithiothreitol (DTT; 3, 5, or 8 mM), thapsigargin (Tg; 10, 50, or 500nM)
or vehicle control (ctrl). Reporter gene activities from three independent experiments in duplicates are shown as the LucF/LucR ratio. d
Representative Western blot of the increased expression of ERα46 observed in stressed MDA-MB-231 cells transfected with cDNA expressing
ERα66. *P < 0.05, **P < 0.01, ***P < 0.001, versus control (Kruskal-Wallis) ns not significant
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were found to be significantly increased in response to UPR
inducers (i.e., DTT and thapsigargin) (Fig. 3c). These induc-
tions correlated with the observed increase in ERα46 pro-
tein levels after stress induction in cells stably transfected
with the full-length ESR1 cDNA (Fig. 3d). As a control, we
used siRNA directed against LucR which diminished LucF
activity (Additional file 1: Figure S5B and C), demonstrating
the absence of either an internal promoter in the interven-
ing sequence or stress-induced cryptic alternative splicing
that could have shunted the LucR cistron. Taken together,
these data suggest that ERα46 can be produced by stress
inducers via an IRES-dependent mechanism.
ERα46 antagonizes the ERα66-mediated proliferative re-
sponse of MCF-7 cells to E2 in a dose-dependent manner
Next, we explored the impact of a high expression level of
ERα46 on E2-induced proliferation of breast tumor cells
using MCF-7 cell lines which were engineered to overex-
press a tet-inducible ERα46 (Fig. 4). Proliferation in re-
sponse to E2 is not influenced by tetracycline treatment as
demonstrated using MCF7-B0 sub-clone which expresses
an empty vector. By contrast, the proliferation in response
to E2 is partially abrogated in the MCF-B1 clone after
tetracycline induction (ratio of ERα46/66 close to 1) and
almost completely abolished using the MCF7-B2 clone
(ratio of ERα46/66 close to 10) which expresses the high-
est expression level of ERα46. These results indicate that
overexpression of the ERα46 isoform inhibited the E2-
mediated cell proliferation, with inhibition being propor-
tional to the expression of ERα46.
Identification of cofactors that differentially interact with
ERα66 and ERα46
This inhibition of proliferation may occur through the
differential recruitment of coregulators by the ERα46
and ERα66 isoforms in the cellular responses induced by
E2. To test this hypothesis, we used the MARCoNI assay
to characterize the interaction of the two ERα isoforms
with 154 unique coregulator-derived motifs, both in
their unliganded (apo) conformation or with concentra-
tions of E2 ranging from 10–12 to 10–7 M, corresponding
to full ligand saturation and receptor activation [26].
The resulting overall binding patterns (Additional file 1:
Figure S6A and B) indicated that, qualitatively, the re-
ceptors bind to the same subset of coregulators, with a
clear response of the ERα46 isoform to E2. However, an
isoform-selective difference in the binding affinities of
both apo and fully-activated receptors was also observed
(Fig. 5a). Further analysis of the E2 response curves evi-
denced that: (i) both isoforms behave similarly for some
interactions (with BRD8 for instance); (ii) some peptides
bind better to one of the isoforms, for example NCOA3
(also named SRC-3) which has a higher affinity for
ERα66 and PRGC1 to ERα46; and (iii) some cofactors
bind to both isoforms equally in their apo conformation,
but increasing E2 concentrations favor their association
with one or the other, as observed for the binding of
EP300 to ERα66 or NROB2 to ERα46 (Fig. 5a). The hier-
archical clustering of ligand-induced modulation of core-
gulator interactions was then performed to look for
differences and was quantified as the log-fold change in
binding (modulation index (MI)) (Fig. 5b). This analysis
confirmed that, although qualitatively the overall re-
sponses looked generally quite similar, there is a quanti-
tative differential modulation with some selective
preference to certain coregulator peptides. Upon E2
binding, an overall increased preference for cofactor
binding to ERα66 over ERα46 was observed, as shown in
Fig. 5c.
We then investigated the potency of the ERα antagonists
4-OH-tamoxifen and fulvestrant in inhibiting cofactor
binding to ERα46 and ERα66 in the presence of E2. The
profile of the EC50 values for 4-OH-tamoxifen and fulves-
trant clearly showed a better efficacy of 4-OH-tamoxifen
than fulvestrant in inhibiting E2-induced binding of the
receptor isoforms to coregulators (Additional file 1:
Figure 6C). However, the potencies of these antagonists to
inhibit binding to ERα46 and ERα66 were comparable
(Fig. 5d). Altogether, these data clearly demonstrate that the
two isoforms show some specificity and heterogeneity in
terms of their binding to coregulators.
MCF7-B0  MCF7-B1   MCF7-B2  
ER 66
ER 46
- tet + tet - tet + tet - tet      +  tet  
a




















Fig. 4 Estrogen receptor alpha (ERα)46 antagonizes the 17β-estradiol
(E2) proliferative response of ERα66 in MCF7 cells. a Expression of the
ERα46 and ERα66 proteins on MCF7 clones analyzed by Western blotting
following tetracycline (tet) treatment to induce the ERα46 expression. b
The proliferative effect of E2 was then analyzed by counting cells after
5 days of stimulation with 10 nM E2. ***P< 0.001. ns not significant

















































Fig. 5 (See legend on next page.)
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Differential gene expression response to E2 mediated by
ERα46 and ERα66
In order to evaluate the impact of differences in coregulator
affinity between the two ERα isoforms in terms of
transcriptional regulation, we aimed at determining the
expression of some target genes in MDA-ERα46 and
MDA-ERα66 cells in response to E2. To directly assess the
correlation between these events and cell proliferation, we
selected a set of genes for their known association with this
process, some of them also described as regulated by E2 in
MCF7 breast cancer cells or MDA-ERα66 cells (Additional
file 1: Figure S7) [36, 37]. The data (Fig. 6 and Additional
file 1: Figure S8) indicate that the majority of the tested
genes are differentially regulated in MDA-ERα46 and
MDA-ERα66 cells. While some genes were found to be reg-
ulated by E2 in MDA cells expressing either ERα66 or
ERα46, albeit at higher levels for the ERα66 (GREB1, TFF1,
and PDGFB), some genes were specifically regulated by the
ERα46 (MAPPK14 and CDC14A) or the ERα66 (IER3,
CDK6, ASAP1, IL1B, and CCNB2). Moreover, the basal
levels of transcription were also differentially affected by
the expression of these isoforms as compared to naïve
MDAwt cells. Indeed, some genes were specifically affected
by either the ERα66 (CDK5 and IL1B), or the ERα46
(GREB1, TFF1, MAPK14, CDK2, and CCNE1) but also by
both isoforms (PDGFB, IER3, BRCA1, and TNF).
Altogether, these data clearly demonstrate that ERα46 and
ERα66 have different transcriptional activities.
Discussion
The work reported here aimed to analyze the expression
levels and characteristics of the overlooked ERα46 isoform
in breast tumor samples. We have clearly shown that
ERα46 is expressed in the majority of human breast tu-
mors tested (more than 70%) with highly variable expres-
sion levels, sometimes even more abundant than ERα66.
Importantly, the ERα46/ERα66 expression ratio negatively
correlated with tumor grade: poorly-differentiated tumors
(of higher grade and larger size) presented lower amounts
of ERα46. These data indicate that this shorter isoform
may have a potential clinical relevance. Unfortunately,
since this retrospective study started in 2011, it is too early
to further analyze any correlation between the abundance
of ERα46 and overall survival or recurrence of disease.
(See figure on previous page.)
Fig. 5 Ligand-specific coregulator binding profiles. Interactions of the estrogen receptor alpha (ERα)46 and ERα66 proteins with coregulator motifs were
measured using MARCoNI peptide arrays. Interactions were evaluated at different concentrations of E2, ranging from 10–12 to 10–7 M. a Examples of dose-
dependent E2-mediated modulation of ERα46 and ERα66 interactions with individual coregulator motifs to illustrate that the two proteins bind to coregu-
lators with differential affinities. b Heatmap showing hierarchical clustering (Euclidean distance, average linkage) of E2-mediated interactions (represented
as the modulation index (MI)) between ERα46 and ERα66 proteins and peptides representing coregulator-derived binding motifs. MI is expressed as log of
fold changes relative to vehicle. Zoom outs from the left and the right main clusters are shown below. c Boxplot representation of E2 potency for the
modulation of coregulator binding of the two isoforms, using EC50 values obtained with the curve fit R
2 > 0.8. d Mean of all EC50 (logM) values of the ability












































































































































































Fig. 6 Differential gene expression and response to 17β-estradiol (E2) in
MDA-ERα46 and MDA-ERα66 cells. a The relative expression of a subset
of genes was evaluated in MDA, MDA-ERα46, and MDA-ERα66 cells by
quantitative RT-PCR following a 4-h treatment with E2 or ethanol as
vehicle (V). Data were normalized to those obtained for the Rplp0 gene.
Results shown within the heatmap are expressed as the mean log2 of these
expression values normalized to those obtained in the control MDA cell
line. b. Significant gene regulations by E2 in MDA-ERα46 and MDA-ERα66
cells or significant different basal gene expression between naïve MDA cells
and estrogen receptor (ER) isoforms expressing cells are shown as heatmaps
of P values. c. Examples of gene expression data obtained on six genes
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This criterion requires a time period of 15–20 years due
to delayed tumor relapses of ERα-positive tumors [38].
A previous study reported the expression of a 47-kDa
isoform in human breast cancer that is able to bind to
radioactive tamoxifen aziridine, which could be the same
as the 46-kDa ERα isoform described here [20]. Using elec-
trophoresis with radiolabeled tamoxifen, the authors found
that 49% of tumor samples to express the 67- and the 47-
kDa protein entities, whereas 36% contained only the lon-
gest form. Our proteomic analysis is the first to definitively
identify the band detected by Western blot as an ERα iso-
form deprived of the A/B domain.
Our results also show that several of the antibodies cur-
rently used for the diagnosis of breast cancer are unable to
detect the ERα46 isoform. Indeed, the 1D5, 6 F11, and EP1
antibodies are directed against the A/B domain, which is ab-
sent in ERα46 (Fig. 6). As a consequence, the hormone-
dependent characterization of the tumor, presently performed
by immunohistochemistry, may only be based on the expres-
sion level of ERα66. This finding highlights the importance of
the choice of antibodies used for the diagnosis of breast can-
cer, which able or not to detect the ERα46 isoform.
Furthermore, we found that ERα46 expression level was
related to tumor size, suggesting that expression of the
46-kDa isoform in breast tumors could be associated with
a limited tumor growth. Such a hypothesis is supported by
previous studies demonstrating that ERα46 antagonizes
the proliferative effects induced by ERα66 activation both
in vitro in MCF7 cells [17] and SaOS osteosarcoma cells
[9], as well as in colorectal tumor tissues [12]. Its expres-
sion could therefore maintain a low tumor volume, pos-
sibly by stimulating apoptosis [12]. We confirmed these
data and also found that increasing the amount of ERα46
in MCF7 cells decreases their proliferative response to E2
in a dose-dependent manner. Importantly, other studies
have linked the N-terminal region of ERα with cell prolif-
eration. Merot et al. [39] used in vitro systems to show
that the respective contribution of AF-1 and AF-2 towards
ERα transcriptional activity varies upon the stage of cell
differentiation. This key role of AF-1 was also demon-
strated physiologically in the uterus, a tissue that is highly
sensitive to the proliferative actions of E2 in vivo. Indeed,
it was shown that E2 had no proliferative action on uter-
ine epithelial cells in ERα-AF10 mice, which express an
AF-1-deficient 49-kDa ERα isoform [19]. ERα has been
described as being at the crossroads of paracrine or auto-
crine growth factor and endocrine estrogenic signaling
[40], and its activity can be controlled in the absence of E2
through phosphorylation cascades induced by insulin-like
growth factor (IGF)-1, epidermal growth factor (EGF), or
fibroblast growth factor (FGF)-2. Importantly, most of the
residues of ERα that have so far been implicated in these
E2-independent responses or in the modulation of ERα
activities in response to growth factor signaling are located
within the N-terminal region of the protein and constitute
an intrinsic part of AF-1 [41]. Altogether, these data sup-
port the hypothesis that AF-1 is the region of ERα re-
quired for cell proliferation, and that its absence in the
ERα46 isoform is likely to confer specific properties to this
protein compared to the ERα66 isoform.
In our study, we also analyzed the ability of the two iso-
forms to bind cofactors using the MARCoNI assay, and
found that the two isoforms show some heterogeneity in
terms of binding to coregulators. The ability of the two apo-
ERα isoforms to recruit transcription factors to the pS2/
TFF1 promoter was previously compared by Re-ChIP exper-
iments [22]. This study identified that ERα46 specifically re-
cruited components of the Sin3 repressive complex
(NCOR/SMRT) to the TFF1 promoter in the absence of E2.
This was associated with specific inhibition of the basal tran-
scription of the TFF1 gene by the ERα46 isoform. More re-
cently, the quaternary structure of a biologically active ERα-
coactivator complex on DNA has been determined by
cryoelectron microscopy [42]. This study showed the loca-
tion of the AF-1 domain in the complex, which supports a
role in the recruitment of the coactivator SRC-3. Interest-
ingly, in our assay we also found a stronger binding of
ERα66 to some peptides derived from SRC-3 (Fig. 5b). In
contrast, the ERα46 isoform was found to bind to NRB02
better than the ERα66 isoform. NRB02 acts as a negative
regulator of receptor-dependent signaling pathways [43].
These data therefore underline the importance of the AF-1
domain for full transcriptional activation of the ERα-
coactivator complex. Indeed, our study also demonstrates a
differential gene expression induced by ERα46 or ERα66 at
the basal level but also in response to E2. Interestingly,
among these differentially regulated genes, ERα46 specific-
ally upregulated theMAPK14 and CDC14 genes in the pres-
ence of E2 (respectively 20- and 1.7-fold) as opposed to the
ERα66 isoform. These genes are implicated in the suppres-
sion of the cell proliferation [44, 45] and these regulations
may at least partly explain the reduced E2-mediated prolifer-
ative response observed when ERα46 is co-expressed. Al-
though not significant, the originally identified proapoptotic
HRK gene [46] also exhibited a slight tendency to be specif-
ically regulated by the ERα46 (twofold, P= 0.09).
Our observations raise the hypothesis that the presence
of the short ERα46 isoform in breast tumors could indicate
a more favorable prognosis. Such an assessment is also
supported by the study of Klinge et al. who indicated that
almost 40% of patients developing a secondary tamoxifen
resistance exhibit a reduced expression of ERα46 [13]. This
supports the idea that endocrine resistance is associated
with a decreased expression of ERα46 and thus with poor
breast cancer prognosis. Subtle interactions between these
isoforms could influence the action of selective estrogen
receptor modulators (SERMs) against tumor growth and
metastasis. Interestingly, tamoxifen antagonizes the AF-2
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of both the ERα66 and ERα46 isoforms, but at the same
time acts as an agonist on AF-1 of ERα66 in a tissue-
dependent manner. Due to the lack of AF-1, tamoxifen
cannot elicit such an action on ERα46. As shown in our
analysis with the MARCoNI assay, ERα46 appears to be as
potent as the ERα66 in dissociating coregulatory binding in
response to tamoxifen or fulvestrant. However, since these
interactions are very complex, further investigations are
needed in tumor samples in vivo.
Altogether, these data point out the importance of the ex-
pression of both ERα isoforms in breast tumors. In the
absence of an ERα46-specific antibody, automated immuno-
blot analyses would be necessary to render ERα46 detection
practically feasible in breast cancer diagnosis. However, it
cannot be ruled out that new techniques based on structural
properties of the two estrogen receptors could appear in the
future [47]. Further characterization of ERα46 will then be
needed to refine both prognosis and therapy. Although the
exact mechanisms accounting for the expression of the
ERα46 isoform still remain to be clarified, three potential
processes have been identified: (i) alternative splicing could
generate an mRNA deficient in the nucleotide sequence cor-
responding to exon 1 encoding the A/B domain [14]; (ii)
proteolysis, as has also been suggested in human breast tu-
mors [15] and in the mouse uterus [48]; and (iii) an IRES lo-
cated within the full length mRNA could allow the initiation
of translation at a downstream ATG which encodes methio-
nine 174 in the human ERα66 [16] (Fig. 7). Unfortunately,
our proteomic approach did not identify peptides close to
this initiation codon. One potential explanation for this is
1ESR1 gene 2 3 4 5 6 7 85’UTR
ATG1 ATG174/176 TGA
2 3 4 5 6 7 8
TGA
Alternative splicing of exon1
(shorter mRNA)Splicing (mRNA)
3’UTR1 2 3 4 5 6 7 8
ATG1 TGA
IRES




184 264302 553 595
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Fig. 7 Possible mechanisms to generate the estrogen receptor alpha (ERα)46 and epitope mapping of the antibodies used in this work. ERα46
can be generated either by alternative splicing of the first coding exon [16], by internal ribosomal entry site (IRES)-dependent translation from the
full-length ESR1 transcript [14], or by proteolysis of ERα66 by as-yet unknown proteases [15]. It should be emphasized that these three different
mechanisms could concur to generate the ERα46 isoform, which, to the best of our knowledge, is a unique feature among proteins. AF activation
function, DBD DNA-binding domain, H Hinge domain, LBD ligand-binding domain
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the presence of lysine and arginine residues (target residues
for trypsin) in the vicinity to the two potential initiation co-
dons (KGSMAMESAKETRY). The length of the peptides
generated after complete trypsin digestion may be too short
to be identified despite the high dynamic range of the nano-
LC-MS/MS system used for the proteomic analysis. At this
stage, it is not possible to determine the respective roles of
the different mechanisms of ERα46 generation. However, we
provide evidence that an IRES-dependent alternative trans-
lational initiation under stress conditions could lead to the
generation of ERα46. This is further supported by the asso-
ciation of the ERα mRNA, along with other IRES-
containing mRNAs, to polysomes in apoptotic MCF7 cells
in which cap-dependent translation is repressed [49]. More-
over, 4E-BP1, a negative regulator of cap-dependent mRNA
translation, was found to be overexpressed in breast tumors
compared to healthy epithelium, suggesting that transla-
tional mechanisms such as IRES might be active [50]. Inter-
estingly, genes such as such as Apaf-1, DAP5, CHOP, p53,
etc., that are also selectively translated by an IRES-driven
mechanism, allow the cells to fine-tune their responses to
cellular stress and, if conditions for cell survival are not re-
stored, to proceed with final execution of apoptosis [51]. Al-
though the significance of induction of ERα46 by cellular
stress remains unknown, this isoform of ERα could be part
of an orchestrated IRES-driven response, and contribute to
slowing down of the proliferative response to E2.
Conclusions
This study demonstrates that a shorter ERα46 isoform pre-
viously ignored in diagnosis is frequently expressed in ERα-
positive breast tumors, as revealed by Western blot analysis.
Careful attention should therefore be taken in the choice of
antibodies used for immunohistochemistry as several do
not to detect the expression of the ERα46 isoform. We have
demonstrated that this shorter isoform can differentially
bind to coregulators in response to E2 which might modu-
late the transcriptional hormonal response. This highlights
the potential importance of this shorter isoform in E2
signaling and its antiproliferative actions in breast cancer.
We indeed found a clear inverse correlation between tumor
size and ERα46 levels. Thus, due to the importance of ERα
and hormonal treatments in the management of breast
cancers, ERα46 expression should now be further studied.
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Additional file 1: Figure S1. Clinical parameters of the breast tumor
samples. IDC invasive ductal carcinoma, ILC invasive lobular carcinoma.
Figure S2. Expression of Flag-ERα36 in transiently transfected MDA-
MB231 as detected by immunocytochemistry using an anti-Flag antibody.
Figure S3. Analysis of potential correlation between the clinical parame-
ters of the breast tumor samples and the expression of ERα46 isoform. A
significant P value (indicated in red) was only found between ERα46 ex-
pression and HER-2 positive breast tumors. IDC invasive ductal carcinoma,
ILC invasive Lobular Carcinoma. Figure S4. Results of the proteomic
analysis of the ERα46 protein detected in tumor samples. A) Western blot
with the SP1 antibody obtained after immunoprecipitation of ERα with
HC20 antibody in two human tumors overexpressing the putative
ERα46 isoform. B and C) Sequence coverage obtained from the peptides
identified by proteomic analysis shown in bold red on ERα66 and on ERα46
isoforms M (methionine): putative translational start sites generating the
ERα46 isoform. Figure S5. The stress-induced increase in LucF activity
is reproducible in MCF7 cells (A) and is not due to the generation of
mono-cistronic LucF transcripts via an internal promoter or cryptic
splicing as observed in MDA-Lenti-AB exposed to two siRNAs-lucR
(B and C). Figure S6. Modulation profiles of the interaction of ERα46
(red) and ERα66 (blue) with coregulators in A) Apo proteins and B) in
response to E2 binding. C) Profile of EC50 values of 4-OH-tamoxifen-
(red) and fulvestrant- (blue) induced modulation of ERα46 and ERα66
coregulators interaction when use in antagonists mode with 6.3 nM E2.
Figure S7. List of primers used in the expression profiling of target genes.
Figure S8. Fold-changes (FC) in gene expression± SEM in MDA-ERα46 and
MDA-ERα66 cells in response to 4-h treatment with E2 (10–8 M). P values
were determined by Mann-Whitney test. Significant P values are indicated
in red. (PPTX 939 kb)
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